Israel-based ForSight Robotics has completed a Series B funding round, raising $125m to fuel the growth phase of the robotic surgery platform intended for cataract and other eye conditions.
Claimed to be a world first, the ORYOM platform is tailored to reduce the physical load on surgeons and improve surgical precision. ForSight is gearing up to introduce first-in-human trials within the year.
Spearheaded by Eclipse, the round also included substantial contributions from an undisclosed investor, alongside Intuitive Surgical founder Dr Fred Moll, Reiya Ventures, the Adani Group, and other current investors.
This latest financial injection brings the company’s total funding to $195m.
Related: Corvia Medical raises $55m to complete confirmatory heart shunt trial
ForSight noted that the platform leverages AI-based algorithms, computer vision, and micromechanics to provide manoeuvrability and dexterity.
Capable of reaching any point in the human eye, the platform claims to facilitate navigation through difficult angles and ensures access to anterior and posterior segments, enabling future glaucoma and retinal surgical treatments.
Using the platform, more than 24 ophthalmic surgeons have already performed several procedures on animal eye models.
The company plans to begin robotic cataract surgery clinical trials in the upcoming year.
ForSight Robotics’ chief medical officer, president, and co-founder Dr Joseph Nathan said: “We see ophthalmology as the next frontier in the robotics revolution – much like general surgery was before the rise of Intuitive Surgical. With a comparable market size and an urgent global need, our opportunity ahead is immense.
“Through our latest funding round, we will bring the same level of transformative impact to eye surgery, with technology designed specifically for its unique precision and complexity.”
ForSight has formed a strategic advisory board comprising leaders in surgical robotics. They include MAKO Surgical Corp founder Rony Abovitz and Dr Fred Moll, who recently joined ForSight’s board of directors.
